Royal Bank Of Canada Alvotech Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.4 - $14.51 $15,139 - $19,269	-1,328 Reduced 99.33%	9 $0
Q1 2024 Nov 05, 2024	BUY	$11.36 - $17.27 $15,086 - $22,934	1,328 Added 14755.56%	1,337 $16,000
Q1 2024 May 15, 2024	BUY	$11.36 - $17.27 $13,018 - $19,791	1,146 Added 600.0%	1,337 $16,000
Q4 2023 Feb 14, 2024	BUY	$8.55 - $11.48 $8 - $11	1 Added 0.53%	191 $2,000
Q3 2023 Nov 14, 2023	SELL	$8.12 - $10.07 $1,550 - $1,923	-191 Reduced 50.13%	190 $1,000
Q2 2023 Aug 14, 2023	BUY	$6.9 - $13.85 $2,628 - $5,276	381 New	381 $2,000

15.5M

Ticker ALVO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 248,650,000
Market Cap $2.96B
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.